Oncternal Therapeutics Inc

NASDAQ:ONCT  
4.98
0.00 (0.00%)
Products, Regulatory

Oncternal Therapeutics Announces Presentation Of Interim Phase 1 Clinical Trial Data For TK216

Published: 09/21/2020 12:17 GMT
Oncternal Therapeutics Inc (ONCT) - Oncternal Therapeutics Announces Presentation of Interim Phase 1 Clinical Trial Data for Tk216 in Patients With Relapsed/refractory Ewing Sarcoma at Esmo Virtual Congress 2020.
Oncternal Therapeutics - Tk216 Has Been Generally Well Tolerated in Trial.
Oncternal Therapeutics - No Unexpected Off-target Toxicities of Tk216 Have Been Observed in Trial.